Skip to main content
. 2013 May 14;54(4):865–874. doi: 10.3349/ymj.2013.54.4.865

Fig. 2.

Fig. 2

Kaplan-Meier survival plots for patients with three tumor genotypes in metastatic lung adenocarcinoma treated with EGFR tyrosine kinase inhibitors (TKIs): EGFR mutation (n=41), KRAS mutation (n=8), and WT/WT (n=47). (A) Median OS with EGFR TKI treatment (26.7 months for EGFR mutation vs. 8.2 months for WT/WT vs. 9.2 months for KRAS mutant, p=0.001). (B) Median PFS (12.8 months for EGFR mutation vs. 1.2 months for KRAS mutation vs. 1.9 months for WT/WT, p<0.001).